OncoMatch/Clinical Trials/Ivonescimab

Ivonescimab (AK112) Clinical Trials

Ivonescimab (AK112) is a bispecific antibody that simultaneously blocks the PD-1 immune checkpoint and inhibits vascular endothelial growth factor (VEGF), combining immunotherapy and anti-angiogenic mechanisms in a single molecule. In the HARMONi-2 trial conducted in China, ivonescimab demonstrated superior progression-free survival versus pembrolizumab as first-line therapy for PD-L1–positive advanced NSCLC, though the trial was conducted in China and Summit's global HARMONi-A trial is an ongoing Phase 3 registrational study for the US market. Summit Therapeutics holds ex-China rights and is running global trials across NSCLC, gastric, cervical, and head and neck cancer at multiple US sites. Most trials require PD-L1 testing; enrollment thresholds vary from PD-L1 ≥1% to ≥50%.